Journal of Neurology

, Volume 256, Supplement 3, pp 293–298 | Cite as

Non-motor symptoms in Parkinson’s disease

Article

Abstract

Parkinson’s disease is a hypokinetic movement disorder with cardinal motor features of bradykinesia, resting tremor and rigidity. However, non-motor symptoms, such as cognitive, neuropsychiatric, sleep, autonomic and sensory disturbances are gaining increasing attention. These non-motor symptoms may be intrinsic to the disease pathology or may be results of treatment with dopaminergic agents. Given that most, if not all, patients with Parkinson’s disease will experience non-motor symptoms, it is important to be sensitive to these phenomena, especially since some non-motor signs may precede motor impairment. Treatment may include interventions independent of traditional, dopaminergic anti-Parkinson therapy or may be tailored to increase or reduce dopamine responsiveness of the symptom.

Keywords

Parkinson’s disease Non-motor symptoms Dopaminergic treatment 

Notes

Conflict of interest statement

The authors have no conflict of interest to declare.

References

  1. 1.
    Anonymous (1999) Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. The Parkinson Study Group. N Engl J Med 340:757–763Google Scholar
  2. 2.
    Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P (2001) Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology 56:730–736PubMedGoogle Scholar
  3. 3.
    Aarsland D, Laake K, Larsen JP, Janvin C (2002) Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 72:708–712PubMedCrossRefGoogle Scholar
  4. 4.
    Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J (2003) Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov Disord 18:287–293PubMedCrossRefGoogle Scholar
  5. 5.
    Boeve BF, Dickson DW, Olson EJ, Shepard JW, Silber MH, Ferman TJ, Ahlskog JE, Benarroch EE (2007) Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease. Sleep Med 8:60–64PubMedCrossRefGoogle Scholar
  6. 6.
    Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, Mathis CA, Moore RY, DeKosky ST (2003) Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 60:1745–1748PubMedCrossRefGoogle Scholar
  7. 7.
    Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211PubMedCrossRefGoogle Scholar
  8. 8.
    Brandt-Christensen M, Kvist K, Nilsson FM, Andersen PK, Kessing LV (2007) Treatment with antiparkinson and antidepressant drugs: a register-based, pharmaco-epidemiological study. Mov Disord 22:2037–2042PubMedCrossRefGoogle Scholar
  9. 9.
    Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, Friedman JH (2002) Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biol Psychiatry 52:438–445PubMedCrossRefGoogle Scholar
  10. 10.
    Brunton S, Kuritzky L (2005) Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg. Curr Med Res Opin 21:71–80PubMedCrossRefGoogle Scholar
  11. 11.
    Brusa L, Petta F, Pisani A, Moschella V, Iani C, Stanzione P, Miano R, Finazzi-Agro E (2007) Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease. Neurology 68:1455–1459PubMedCrossRefGoogle Scholar
  12. 12.
    Cersosimo MG, Benarroch EE (2008) Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov Disord 23:1065–1075PubMedCrossRefGoogle Scholar
  13. 13.
    Comella CL, Tanner CM, Ristanovic RK (1993) Polysomnographic sleep measures in Parkinson’s disease patients with treatment-induced hallucinations. Ann Neurol 34:710–714PubMedCrossRefGoogle Scholar
  14. 14.
    Cummings JL (1992) Depression and Parkinson’s disease: a review. Am J Psychiatry 149:443–454PubMedGoogle Scholar
  15. 15.
    de Groat WC (2006) Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol 147(Suppl 2):S25–S40PubMedCrossRefGoogle Scholar
  16. 16.
    Degen L, Petrig C, Studer D, Schroller S, Beglinger C (2005) Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol Motil 17:821–826PubMedCrossRefGoogle Scholar
  17. 17.
    Dell’Agnello G, Ceravolo R, Nuti A, Bellini G, Piccinni A, D’Avino C, Dell’Osso L, Bonuccelli U (2001) SSRIs do not worsen Parkinson’s disease: evidence from an open-label, prospective study. Clin Neuropharmacol 24:221–227PubMedCrossRefGoogle Scholar
  18. 18.
    Dickson DW, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, Klos KJ, Josephs KA, Frigerio R, Burnett M, Parisi JE, Ahlskog JE (2008) Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease. Acta Neuropathol 115:437–444PubMedCrossRefGoogle Scholar
  19. 19.
    Diederich NJ, Raman R, Leurgans S, Goetz CG (2002) Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol 59:1249–1252PubMedCrossRefGoogle Scholar
  20. 20.
    Eichhorn TE, Oertel WH (2001) Macrogol 3350/electrolyte improves constipation in Parkinson’s disease and multiple system atrophy. Mov Disord 16:1176–1177PubMedCrossRefGoogle Scholar
  21. 21.
    Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 351:2509–2518PubMedCrossRefGoogle Scholar
  22. 22.
    Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, Kurlan R, Parsa M, Pfeiffer R (2003) Longitudinal outcome of Parkinson’s disease patients with psychosis. Neurology 60:1756–1761PubMedGoogle Scholar
  23. 23.
    Fenelon G (2008) Psychosis in Parkinson’s disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr 13:18–25PubMedGoogle Scholar
  24. 24.
    Friedman JH, Berman RM, Goetz CG, Factor SA, Ondo WG, Wojcieszek J, Carson WH, Marcus RN (2006) Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson’s disease. Mov Disord 21:2078–2081PubMedCrossRefGoogle Scholar
  25. 25.
    Frieling H, Hillemacher T, Ziegenbein M, Neundorfer B, Bleich S (2007) Treating dopamimetic psychosis in Parkinson’s disease: structured review and meta-analysis. Eur Neuropsychopharmacol 17:165–171PubMedCrossRefGoogle Scholar
  26. 26.
    Gagnon JF, Postuma RB, Montplaisir J (2006) Update on the pharmacology of REM sleep behavior disorder. Neurology 67:742–747PubMedCrossRefGoogle Scholar
  27. 27.
    Goetz CG, Blasucci LM, Leurgans S, Pappert EJ (2000) Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 55:789–794PubMedGoogle Scholar
  28. 28.
    Goetz CG, Pappert EJ, Blasucci LM, Stebbins GT, Ling ZD, Nora MV, Carvey PM (1998) Intravenous levodopa in hallucinating Parkinson’s disease patients: high-dose challenge does not precipitate hallucinations. Neurology 50:515–517PubMedGoogle Scholar
  29. 29.
    Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ (2001) Treatment of erectile dysfunction with sildenafil citrate (Viagra) in Parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 71:371–374PubMedCrossRefGoogle Scholar
  30. 30.
    Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, Rubin M, Fouad-Tarazi FM (1993) Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 95:38–48PubMedCrossRefGoogle Scholar
  31. 31.
    Kapoor S (2008) Management of constipation in the elderly: emerging therapeutic strategies. World J Gastroenterol 14:5226–5227PubMedCrossRefGoogle Scholar
  32. 32.
    Katzenschlager R, Zijlmans J, Evans A, Watt H, Lees AJ (2004) Olfactory function distinguishes vascular parkinsonism from Parkinson’s disease. J Neurol Neurosurg Psychiatry 75:1749–1752PubMedCrossRefGoogle Scholar
  33. 33.
    Kaufmann H (2006) The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors. J Neural Transm Suppl 47:7–484Google Scholar
  34. 34.
    Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, Gironell A, Garcia-Sanchez C, Martinez-Corral M (2008) Motor changes during sertraline treatment in depressed patients with Parkinson’s disease. Eur J Neurol 15:953–959PubMedCrossRefGoogle Scholar
  35. 35.
    Kurlan R, Cummings J, Raman R, Thal L (2007) Quetiapine for agitation or psychosis in patients with dementia and Parkinsonism. Neurology 68:1356–1363PubMedCrossRefGoogle Scholar
  36. 36.
    Lees AJ, Smith E (1983) Cognitive deficits in the early stages of Parkinson’s disease. Brain 106(Pt 2):257–270PubMedCrossRefGoogle Scholar
  37. 37.
    Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, Marsh L (2004) Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease. Int J Geriatr Psychiatry 19:1–8PubMedCrossRefGoogle Scholar
  38. 38.
    Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA (1997) Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: a randomized, double-blind multicenter study. Midodrine Study Group. JAMA 277:1046–1051PubMedCrossRefGoogle Scholar
  39. 39.
    Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, Shulman LM, Gronseth G, Weiner WJ (2006) Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:996–1002PubMedCrossRefGoogle Scholar
  40. 40.
    Negre-Pages L, Regragui W, Bouhassira D, Grandjean H, Rascol O (2008) Chronic pain in Parkinson’s disease: the cross-sectional French DoPaMiP survey. Mov Disord 23:1361–1369PubMedCrossRefGoogle Scholar
  41. 41.
    Ondo WG, Perkins T, Swick T, Hull KL Jr, Jimenez JE, Garris TS, Pardi D (2008) Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study. Arch Neurol 65:1337–1340PubMedCrossRefGoogle Scholar
  42. 42.
    Ouslander JG (2004) Management of overactive bladder. N Engl J Med 350:786–799PubMedCrossRefGoogle Scholar
  43. 43.
    Poewe W, Wolters E, Emre M, Onofrj M, Hsu C, Tekin S, Lane R (2006) Long-term benefits of rivastigmine in dementia associated with Parkinson’s disease: an active treatment extension study. Mov Disord 21:456–461PubMedCrossRefGoogle Scholar
  44. 44.
    Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C (2007) Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord 22:313–318PubMedCrossRefGoogle Scholar
  45. 45.
    Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, Fernandez HH, Trieschmann MM, Reichwein S, Simuni T (2005) Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 76:934–939PubMedCrossRefGoogle Scholar
  46. 46.
    Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128:1314–1322PubMedCrossRefGoogle Scholar
  47. 47.
    Sahai A, Khan MS, Arya M, John J, Singh R, Patel HR (2006) The overactive bladder: review of current pharmacotherapy in adults. Part 2: treatment options in cases refractory to anticholinergics. Expert Opin Pharmacother 7:529–538PubMedCrossRefGoogle Scholar
  48. 48.
    Schenck CH, Bundlie SR, Mahowald MW (1996) Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46:388–393PubMedGoogle Scholar
  49. 49.
    Schestatsky P, Kumru H, Valls-Sole J, Valldeoriola F, Marti MJ, Tolosa E, Chaves ML (2007) Neurophysiologic study of central pain in patients with Parkinson disease. Neurology 69:2162–2169PubMedCrossRefGoogle Scholar
  50. 50.
    Seeman P, Caruso C, Lasaga M (2008) Memantine agonist action at dopamine D2High receptors. Synapse 62:149–153PubMedCrossRefGoogle Scholar
  51. 51.
    Stacy M (1999) Managing late complications of Parkinson’s disease. Med Clin North Am 83:469–481Google Scholar
  52. 52.
    Stacy M (2002) Sleep disorders in Parkinson’s disease: epidemiology and management. Drugs Aging 19:733–739PubMedCrossRefGoogle Scholar
  53. 53.
    Stamey W, Davidson A, Jankovic J (2008) Shoulder pain: a presenting symptom of Parkinson disease. J Clin Rheumatol 14:253–254PubMedCrossRefGoogle Scholar
  54. 54.
    Uc EY, Rizzo M, Anderson SW, Qian S, Rodnitzky RL, Dawson JD (2005) Visual dysfunction in Parkinson disease without dementia. Neurology 65:1907–1913PubMedCrossRefGoogle Scholar
  55. 55.
    Verbaan D, van Rooden SM, Visser M, Marinus J, van Hilten JJ (2008) Nighttime sleep problems and daytime sleepiness in Parkinson’s disease. Mov Disord 23:35–41PubMedCrossRefGoogle Scholar
  56. 56.
    Wesnes KA, McKeith I, Edgar C, Emre M, Lane R (2005) Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 65:1654–1656PubMedCrossRefGoogle Scholar
  57. 57.
    Yamamoto T, Sakakibara R, Hashimoto K, Nakazawa K, Uchiyama T, Liu Z, Ito T, Hattori T (2005) Striatal dopamine level increases in the urinary storage phase in cats: an in vivo microdialysis study. Neuroscience 135:299–303PubMedCrossRefGoogle Scholar
  58. 58.
    Zangaglia R, Martignoni E, Glorioso M, Ossola M, Riboldazzi G, Calandrella D, Brunetti G, Pacchetti C (2007) Macrogol for the treatment of constipation in Parkinson’s disease. A randomized placebo-controlled study. Mov Disord 22:1239–1244PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Department of NeurologyThe Ohio State UniversityColumbusUSA
  2. 2.Division of NeurologyDuke University Medical CenterDurhamUSA

Personalised recommendations